Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Inclusion Criteria: * Able and willing to give written informed consent and authorize HIPAA. * Participants with migraine with or without aura fulfilling the International Headache Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification (ICHD) 2004). * History of disabling migraine for at least 1 year. * Migraine Disability Association (MIDAS) score ≥11. * Migraine onset before the age of 50 years. * History of 3 - 8 migraine attacks per month (\< 15 headache days per month). * Male or female, aged 18 years or above. * Females of child-bearing potential must be using or willing to use a highly effective form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD), abstinence or vasectomized partner). * Able and willing to complete an electronic diary to record details of the migraine attack treated with study drug. Exclusion Criteria: * Any medical condition or clinical laboratory test which in the judgment of the Investigator makes the participant unsuitable for the study. * Pregnant or breast-feeding women. * Women of child-bearing potential not using or not willing to use highly effective contraception. * Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets, or any sensitivity to lasmiditan. * History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the participant at increased risk of seizures. * History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular disorders. * History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or neuropathy). * History within the previous three years or current evidence of abuse of any drug, prescription or illicit, or alcohol. * History of orthostatic hypotension with syncope. * Significant renal or hepatic impairment. * Participant is at imminent risk of suicide (positive response to question 4 or 5) on the Columbia-Suicide Severity Rating Scale (C-SSRS) or had a suicide attempt within six months prior to screening. * Previous participation in this clinical trial. * Participation in any clinical trial of an experimental drug or device in the previous 30 days. * Known Hepatitis B or C or HIV infection. * History, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (e.g. hemicranias continua, medication overuse headache) where headache frequency is ≥15 headache days per month. * Use of more than 3 doses per month of either opiates or barbiturates. * Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within three (3) months prior to Screening/Visit 1. * Participants who are employees of the sponsor. * Relatives of, or staff directly reporting to, the Investigator.